Search - tctmd.com

Displaying 221 - 240 of 410

Sort: Relevancy | Date

News Conference News AHA 2019

ISCHEMIA Countdown Begins, but a ‘Black-and-White’ Answer Is Uncertain

Shelley Wood

October 25, 2019

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

News

Analysis Hints at Survival Benefit With Revascularization in Stable Patients With Myocardial Ischemia

Michael O'Riordan

September 24, 2019

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

News Conference News ESC 2019

New ‘Chronic Coronary Syndrome’ Guidelines Stress There’s Nothing Stable About CAD

Shelley Wood

August 31, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Daily News

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

Caitlin E. Cox

August 21, 2019

News Daily News

Baseline Ischemia Not Linked to 10-Year Events in Stable CAD: MASS II Analysis

Shelley Wood

July 23, 2019

News Daily News

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

Michael O'Riordan

July 03, 2019

News Daily News

Higher Risk of Intracranial Hemorrhage With Aspirin in Primary Prevention

Michael O'Riordan

May 20, 2019

News Daily News

AHA Statement on MINOCA Provides a Standard Definition, Clinical Care Algorithms

Yael L. Maxwell

April 03, 2019

News Daily News

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

Michael O'Riordan

March 01, 2019

News Daily News

Majority of SCAD Lesions Heal With Conservative Treatment

Michael O'Riordan

February 27, 2019

News Daily News

Irrational Exuberance or Evidence-Based Medicine: What Role for CT Angiography in Stable Chest Pain?

Michael O'Riordan

January 11, 2019

News Daily News

US and European DAPT Guidelines More Alike Than Different, Say Experts

Yael L. Maxwell

December 03, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2018

Shelley Wood

November 30, 2018

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News AHA 2018

Rivaroxaban Lowers Thromboembolic Risk in HF Patients: COMMANDER HF

Todd Neale

November 11, 2018

News Conference News AHA 2018

T-Time: Alteplase Infusion No Help for Failed Reperfusion in STEMI PCI

Shelley Wood

November 11, 2018

Advertisement

ISCHEMIA Countdown Begins, but a ‘Black-and-White’ Answer Is Uncertain

Recurrent Events Common Among Young Patients With CAD

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Analysis Hints at Survival Benefit With Revascularization in Stable Patients With Myocardial Ischemia

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

New ‘Chronic Coronary Syndrome’ Guidelines Stress There’s Nothing Stable About CAD

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

Baseline Ischemia Not Linked to 10-Year Events in Stable CAD: MASS II Analysis

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

Higher Risk of Intracranial Hemorrhage With Aspirin in Primary Prevention

AHA Statement on MINOCA Provides a Standard Definition, Clinical Care Algorithms

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

Majority of SCAD Lesions Heal With Conservative Treatment

Irrational Exuberance or Evidence-Based Medicine: What Role for CT Angiography in Stable Chest Pain?

US and European DAPT Guidelines More Alike Than Different, Say Experts

TCTMD’s Top 10 Most Popular Stories for November 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Rivaroxaban Lowers Thromboembolic Risk in HF Patients: COMMANDER HF

T-Time: Alteplase Infusion No Help for Failed Reperfusion in STEMI PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content